

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Pembrolizumab with enfortumab vedotin for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer [ID6607]

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Stakeholders highlighted that:

- women may be diagnosed at a later stage than men
- people ineligible for cisplatin (which may be due to disability or age) have fewer effective neoadjuvant treatment options so could benefit more from a new treatment
- some patients living in remote or rural areas have to travel long distances for specialist care to larger/higher-capacity centres, and travel may discourage patients from accessing care

2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee?

The committee will evaluate pembrolizumab with enfortumab vedotin within the population in its marketing authorisation. The committee may consider people eligible and not eligible for cisplatin as separate subgroups if the evidence allows.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

Subgroups have been added to consider people who are and are not eligible for cisplatin-based therapy separately where evidence allows.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

None.

Approved by Principal Technical Adviser: Elizabeth Bell

Date: 25th February 2026